| Product Code | GMD08964 |
|---|---|
| Publication Date | July 2009 |
| Publisher | Global Markets Direct |
| Product Type | Report |
| Pages | 16 |
Amorfix Life Sciences Ltd. - Financial and Strategic Analysis Review
Amorfix Life Sciences Ltd. (Amorfix) is a theranostics company engaged in developing therapeutic products and diagnostic devices for treatment of brain-wasting diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and variant Creutzfeldt - Jakob disease (vCJD). The company intends to develop diagnostic kits, biologic therapeutics, drug therapeutics, and prophylactics, such as vaccines for the treatment of aggregated misfolded proteins (AMP). The company's lead programs include a diagnostic blood screening test for vCJD and a therapy for ALS. The company is headquartered at Mississauga in Ontario, Canada.
Global Markets Direct's Amorfix Life Sciences Ltd. - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of Amorfix Life Sciences Ltd.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.
PDF:Delivered by email usually within 12 to 24 UK business hours.
© 2010 | Report Buyer is a trading name for Piribo Ltd. Registered in England and Wales No. 05051530 | VAT Reg No. GB 839 4556 85